Novel Interferons for Treatment of Hepatitis C Virus
Novel Interferons for Treatment of Hepatitis C Virus
复制标题
DOI：
10.1016/j.cld.2009.05.004
复制
发表时间：
2009-08-01
影响因子：
5.1
通讯作者：
Nelson, David R.
中科院分区：
文献类型：
--
作者：
Clark, Virginia;Nelson, David R.
目前治疗丙型肝炎的标准治疗是聚乙二醇干扰素和利巴韦林。尽管大量新的口服药物正在开发中，但干扰素仍可能是未来治疗的支柱。干扰素具有独特的抗病毒和免疫调节特性，这在限制对蛋白酶抑制剂的耐药性和提高疗效方面至关重要。因此，随着新的治疗方案进入临床竞技场，优化药代动力学和促进对干扰素给药方案的依从性将变得更加关键。这篇评论强调了新的干扰素的发展，可能提供治疗优势，目前可用的配方。
The current standard of care for treatment of hepatitis C is pegylated interferon and ribavirin. Despite the large number of new oral agents under development, interferon will likely remain the backbone of future therapy. Interferon has unique antiviral and immunomodulatory properties, which have been critical in limiting resistance to protease inhibitors and improving efficacy. Hence, optimizing pharmacokinetics and promoting adherence to interferon dosing regimens will become even more critical as new regimens enter the clinical arena. This review highlights novel interferons under development that may offer therapeutic advantages over the formulations currently available.